FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2321043971> ?p ?o ?g. }

• W2321043971 endingPage "414" @default.
• W2321043971 startingPage "408" @default.
• W2321043971 abstract "Cop 1 is a random polymer (molecular weight, 14,000 to 23,000) simulating myelin basic protein. It is synthesized by polymerizing L-alanine, L-glutamic acid, L-lysine, and L-tyrosine. It suppresses but does not induce experimental allergic encepnalomyelitis, an animal model of multiple sclerosis. It is not toxic in animals. In a double-blind, randomized, placebo-controlled pilot trial, we studied 50 patients with the exacerbating–remitting form of multiple sclerosis, who self-injected either 20 mg of Cop 1 dissolved in 1 ml of saline or saline alone daily for two years. Six of 23 patients in the placebo group (26 percent) and 14 of 25 patients in the Cop 1 group (56 percent) had no exacerbations (P = 0.045). There were 62 exacerbations in the placebo group and 16 in the Cop 1 group, yielding two-year averages of 2.7 and 0.6 per patient, respectively. Among patients who were less disabled on entry (Kurtzke disability score, 0 to 2), there were 2.7 exacerbations in the placebo group and 0.3 in the Cop 1 group over two years. Among patients who were more affected (Kurtzke disability score, 3 to 6), there was an average of 2.7 exacerbations in the placebo group and 1.0 in the Cop 1 group. Over two years, less disabled patients taking Cop 1 improved an average of 0.5 Kurtzke units; those taking placebo worsened an average of 1.2 Kurtzke units. More disabled patients worsened by 0.3 (Cop 1 group) and 0.4 (placebo group) unit. Irritation at injection sites and rare, transient vasomotor responses were observed as side effects. These results suggest that Cop 1 may be beneficial in patients with the exacerbating–remitting form of multiple sclerosis, but we emphasize that the study is a preliminary one and our data require confirmation by a more extensive clinical trial. (N Engl J Med 1987; 317:408–14.)" @default.
• W2321043971 created "2016-06-24" @default.
• W2321043971 creator A5001693847 @default.
• W2321043971 creator A5016902113 @default.
• W2321043971 creator A5018485236 @default.
• W2321043971 creator A5027823700 @default.
• W2321043971 creator A5030290955 @default.
• W2321043971 creator A5030895600 @default.
• W2321043971 creator A5036630126 @default.
• W2321043971 creator A5038689095 @default.
• W2321043971 creator A5040304249 @default.
• W2321043971 creator A5045401402 @default.
• W2321043971 creator A5050466863 @default.
• W2321043971 creator A5063484882 @default.
• W2321043971 creator A5069614347 @default.
• W2321043971 creator A5078291262 @default.
• W2321043971 creator A5091113056 @default.
• W2321043971 date "1987-08-13" @default.
• W2321043971 modified "2023-09-27" @default.
• W2321043971 title "A Pilot Trial of Cop 1 in Exacerbating–Remitting Multiple Sclerosis" @default.
• W2321043971 cites W1020666978 @default.
• W2321043971 cites W1538307588 @default.
• W2321043971 cites W1906631552 @default.
• W2321043971 cites W1966515926 @default.
• W2321043971 cites W1971067549 @default.
• W2321043971 cites W1987973996 @default.
• W2321043971 cites W2026361275 @default.
• W2321043971 cites W2034735571 @default.
• W2321043971 cites W2042263624 @default.
• W2321043971 cites W2048345403 @default.
• W2321043971 cites W2048880380 @default.
• W2321043971 cites W2052596815 @default.
• W2321043971 cites W2057672045 @default.
• W2321043971 cites W2061997975 @default.
• W2321043971 cites W2104377381 @default.
• W2321043971 cites W2114804450 @default.
• W2321043971 cites W2126974330 @default.
• W2321043971 cites W2130355701 @default.
• W2321043971 cites W2163489852 @default.
• W2321043971 cites W4244031314 @default.
• W2321043971 doi "https://doi.org/10.1056/nejm198708133170703" @default.
• W2321043971 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/3302705" @default.
• W2321043971 hasPublicationYear "1987" @default.
• W2321043971 type Work @default.
• W2321043971 sameAs 2321043971 @default.
• W2321043971 citedByCount "432" @default.
• W2321043971 countsByYear W23210439712012 @default.
• W2321043971 countsByYear W23210439712013 @default.
• W2321043971 countsByYear W23210439712014 @default.
• W2321043971 countsByYear W23210439712015 @default.
• W2321043971 countsByYear W23210439712016 @default.
• W2321043971 countsByYear W23210439712017 @default.
• W2321043971 countsByYear W23210439712018 @default.
• W2321043971 countsByYear W23210439712019 @default.
• W2321043971 countsByYear W23210439712020 @default.
• W2321043971 countsByYear W23210439712021 @default.
• W2321043971 countsByYear W23210439712022 @default.
• W2321043971 countsByYear W23210439712023 @default.
• W2321043971 crossrefType "journal-article" @default.
• W2321043971 hasAuthorship W2321043971A5001693847 @default.
• W2321043971 hasAuthorship W2321043971A5016902113 @default.
• W2321043971 hasAuthorship W2321043971A5018485236 @default.
• W2321043971 hasAuthorship W2321043971A5027823700 @default.
• W2321043971 hasAuthorship W2321043971A5030290955 @default.
• W2321043971 hasAuthorship W2321043971A5030895600 @default.
• W2321043971 hasAuthorship W2321043971A5036630126 @default.
• W2321043971 hasAuthorship W2321043971A5038689095 @default.
• W2321043971 hasAuthorship W2321043971A5040304249 @default.
• W2321043971 hasAuthorship W2321043971A5045401402 @default.
• W2321043971 hasAuthorship W2321043971A5050466863 @default.
• W2321043971 hasAuthorship W2321043971A5063484882 @default.
• W2321043971 hasAuthorship W2321043971A5069614347 @default.
• W2321043971 hasAuthorship W2321043971A5078291262 @default.
• W2321043971 hasAuthorship W2321043971A5091113056 @default.
• W2321043971 hasConcept C126322002 @default.
• W2321043971 hasConcept C142724271 @default.
• W2321043971 hasConcept C1862650 @default.
• W2321043971 hasConcept C203014093 @default.
• W2321043971 hasConcept C204787440 @default.
• W2321043971 hasConcept C27081682 @default.
• W2321043971 hasConcept C2777397205 @default.
• W2321043971 hasConcept C2780640218 @default.
• W2321043971 hasConcept C3020694758 @default.
• W2321043971 hasConcept C71924100 @default.
• W2321043971 hasConcept C90924648 @default.
• W2321043971 hasConceptScore W2321043971C126322002 @default.
• W2321043971 hasConceptScore W2321043971C142724271 @default.
• W2321043971 hasConceptScore W2321043971C1862650 @default.
• W2321043971 hasConceptScore W2321043971C203014093 @default.
• W2321043971 hasConceptScore W2321043971C204787440 @default.
• W2321043971 hasConceptScore W2321043971C27081682 @default.
• W2321043971 hasConceptScore W2321043971C2777397205 @default.
• W2321043971 hasConceptScore W2321043971C2780640218 @default.
• W2321043971 hasConceptScore W2321043971C3020694758 @default.
• W2321043971 hasConceptScore W2321043971C71924100 @default.
• W2321043971 hasConceptScore W2321043971C90924648 @default.
• W2321043971 hasIssue "7" @default.
• W2321043971 hasLocation W23210439711 @default.

• next